Shore Capital reiterated their buy rating on shares of GSK (LON:GSK - Free Report) in a research report report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a GBX 2,000 ($26.55) price objective on the stock.
Other research analysts have also recently issued research reports about the stock. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 ($21.24) price target on shares of GSK in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 1,450 ($19.25) price target on shares of GSK in a research note on Monday, July 21st. Finally, JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a report on Friday, July 18th.
View Our Latest Stock Analysis on GSK
GSK Stock Down 1.5%
Shares of LON:GSK traded down GBX 21.50 ($0.29) during trading hours on Wednesday, hitting GBX 1,396.50 ($18.54). The company's stock had a trading volume of 8,559,338 shares, compared to its average volume of 13,407,056. GSK has a 52 week low of GBX 1,242.50 ($16.49) and a 52 week high of GBX 1,678.68 ($22.28). The company has a market capitalization of £56.67 billion, a price-to-earnings ratio of 22.56, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The firm's fifty day moving average price is GBX 1,434.66 and its 200 day moving average price is GBX 1,426.11.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 ($1.00) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, research analysts expect that GSK will post 175.980975 EPS for the current year.
Insider Activity at GSK
In related news, insider Jonathan Symonds acquired 1,350 shares of the stock in a transaction dated Friday, June 20th. The shares were acquired at an average price of GBX 1,435 ($19.05) per share, with a total value of £19,372.50 ($25,713.43). Also, insider Emma Walmsley sold 5,473 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.23), for a total value of £79,303.77 ($105,261.18). Over the last ninety days, insiders have acquired 1,905 shares of company stock valued at $2,732,835. Company insiders own 1.61% of the company's stock.
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.